Figure 3
From: Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway
Metformin alleviates olanzapine-induced hepatic lipid accumulation by inhibiting PCSK9 and lipid synthesis-related gene expression in vivo and in vitro. mTOR (A) mRNA and (B) protein levels in HepG2 cells and AML12 cells. (C) LC3B mRNA levels in HepG2 cells and AML12 cells. (D) Ratio of LC3B II/LC3B I in HepG2 cells and AML12 cells. (E) PCSK9 mRNA and protein levels in HepG2 cells and AML12 cells treated with the PCSK9 plasmid. (F, G) ORO staining of HepG2 cells and AML12 cells treated with the PCSK9 plasmid. ACC, FAS, SCD1, DGAT1, and DGAT2 mRNA levels in (H) mouse liver tissues, (I) HepG2 cells and (J) AML12 cells. ACC, FAS, SCD1and DGAT1 mRNA levels in (K) HepG2 cells and (L) AML12 cells treated with the PCSK9 plasmid. FAS and SCD1mRNA levels in (M) HepG2 cells and (N) AML12 cells treated with the olanzapine and metformin. CPT1α, SCAD, PPARα, ACOX1 mRNA levels in (O) HepG2 cells and (P) AML12 cells treated with olanzapine; SCAD and PPARα mRNA levels in (Q) HepG2 cells and (R) AML12 cells treated with PCSK9 plasmid; SCAD and PPARα mRNA levels in (S) HepG2 cells and (T) AML12 cells treated with olanzapine and metformin. OLZ, olanzapine; MET, metformin. Data represent the mean ± SEM. ##p < 0.01, ###p < 0.001 vs. control; **p < 0.01, ***p < 0.001 vs. olanzapine; one-way ANOVA plus Tukey’s post-hoc test.
